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a b s t r a c t
A deﬁnable concept of symptomatic remission in schizophrenia has been proposed by the Remission in
Schizophrenia Working Group (RSWG). Nevertheless no studies to date assessed eventual differences in
core symptoms at onset between remitters and non-remitters. The present study evaluated whether the
severity of core symptoms differed among 48 patients with ﬁrst episode schizophrenia (FES), and
whether it predicted long-term (16-years) remission. Particularly, the present study aimed to verify if
RSWG remission criteria might identify a sub-group of patients with mild core symptoms at their ﬁrst
episode. In the present study the severity of core symptoms was signiﬁcantly lower in remitted than in
non-remitted patients; interestingly, ﬁve out of the eight core symptoms already satisﬁed the severity
criteria for remission in most remitted patients. Among the core symptoms only the severity of social
withdrawal predicted the long-term outcome, while age at onset, duration of untreated psychosis and
employment status did not exert any effect. Concluding, patients with FES presenting, mild core
symptoms, particularly low negative symptoms, were more likely to reach long-term remission.
Therefore, RSWG remission criteria seem to identify a subgroup of FES patients with mild severe core
symptoms so with a higher probability to reach remission.
& 2014 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Since the description of dementia praecox (Kraepelin, 1899,
schizophrenia has been conceptualized as a chronic illness and
remission has long been considered largely impossible, with the
consequence that diagnosis and prognosis were viewed as essen-
tially the same (McGlashan, 2008). However, in the recent years
the Remission in Schizophrenia Working Group (RSWG)
(Andreasen et al., 2005) posited that “symptomatic remission is
a deﬁnable concept and an achievable stage in the treatment of
schizophrenia” and proposed criteria for symptomatic remission.
According to such criteria, remission is deﬁned as: “a state in
which patients have experienced an improvement in core symp-
toms, to the extent that these symptoms no longer interfere
signiﬁcantly with daily life”. Core symptoms are those perceived
as diagnostically characteristics for the condition, and eight items
of the Positive and Negative Syndrome Scale (PANSS) were
proposed for their evaluation. Remission is achieved if all eight
items are rated as mild (Andreasen et al., 2005).
According to these criteria a substantial proportion of patients
with schizophrenia (45–70%) (Lambert et al., 2010) can be deﬁned
as remitters at some point during the course of their illness.
However, patients who eventually reach the RSWG remission
condition may be highly heterogeneous. For instance, remitted
patients could have shown, at illness onset, a different severity of
the core symptoms when compared to patients who will not
achieve remission, even though no studies have speciﬁcally
investigated this topic.
Therefore, the present study aimed to evaluate whether
1) patients with ﬁrst episode schizophrenia (FES) who gained
remission after several years of illness differed from non-remitters
with respect to the severity of the core symptoms, and 2) which of
the core symptoms predicted long-term remission. Particularly, we
aimed to verify if RSWG remission criteria identiﬁed a sub-group
of patients with mild core symptoms at their ﬁrst episode.
2. Methods
The study protocol was approved by the local ethic committee. This study is a
part of a more extensive evaluation of outcome in patients with a ﬁrst psychotic
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episode and data on long-term outcome have been already published (Marchesi
et al., 2014).
2.1. Sample
The study participants were recruited from patients who were consecutively
admitted to the Psychiatric Clinic of the University of Parma, from January 1995 to
December 1999, for the ﬁrst psychotic episode. A physician or a psychiatrist
requested the admission for the onset of delusions, hallucinations or behavior
disorganization.
Patients were included in the study if: 1) they were aged over 17 years; 2) they
were hospitalized for the ﬁrst time in a psychiatric unit for a ﬁrst psychotic
episode; 3) they were discharged with a diagnosis of Schizophrenia, according to
the DSM-IV; 4) they accepted to be revaluated after many years from the index
admission; and 5) they gave a written informed consent during the index
hospitalization.
Patients were excluded from the study if: 1) they were affected by drug abuse
or drug dependence, delirium, mental retardation or organic mental disorders; 2)
they were previously treated with psychotropic medication; 3) they did not assure
treatment adherence or they discontinued the treatment program after discharge
from hospital for more than two consecutive visits (see follow-up evaluation).
2.2. Assessment
2.2.1. Baseline assessment
The baseline evaluation was carried out within the ﬁrst week of hospitalization.
Socio-demographic variables recorded at baseline were: age, gender, years of
education, marital and employment status, housing situation, age at onset of
schizophrenia and the time passed from the onset of psychotic symptoms or
behavioral changes to the time of hospitalization (i.e., when patients received
treatment for the ﬁrst time).
The diagnosis of schizophrenia was assessed by means of the Structured
Clinical Interview for Axis I DSM-IV disorders, carried out by trained psychiatrists.
Symptom severity was measured with the Positive and Negative Syndrome
Scale (PANSS).
2.2.2. Follow-up evaluation
After hospital discharge, patients accessed to continuous and, reasonably
comprehensive, public mental health services (Amaddeo et al., 2012), where they
attended nearly monthly visits.
During each visit their psychopathological condition, treatment adherence,
medications prescription, and use of illicit drugs were clinically monitored and
these data were freely accessible from the therapists over the 16 year follow-up.
Patients were re-examined in 2010 by a psychiatrist, blind to the baseline
evaluation. The follow-up assessment consisted in the administration of SCID-I and
PANSS. After eight months the patients were re-evaluated with the PANSS in order
to determine whether the time criterion of 6 months requested by RSWG for
remission was satisﬁed. Only after the follow-up assessment, patients were deﬁned
in remission (R) or in non-remission (NR), according to both severity and time
criteria proposed by the RSWG.
2.3. Treatment
All patients received antipsychotic medications. In the effort to maximize
treatment adherence, a medication control by relatives was recommended and the
count of pills was performed at any time the medication was prescribed. The use of
long-acting compounds was proposed to patients who did not assure treatment
adherence.
2.4. Data analysis
Before the start-up of the study and the follow-up evaluations an inter-rater
reliability was calculated for the diagnosis of schizophrenia (baseline: k¼0.92;
follow-up: k¼0.95) and for the PANSS core symptoms scores (baseline: k¼0.72–
0.86; follow-up: k¼0.73–0.90).
The clinical and socio-demographic features were compared in R and in NR
using two-tailed Student's t-test for continuous variables and Fischer's exact test
for categorical variables.
Lastly, a logistic regression analysis (a stepwise method) was applied to
evaluate whether core symptoms severity at baseline together with gender, age
at onset, DUP and working status (independent variables) predicted the remission
status at follow-up (dependent variable: R vs NR).
The statistical software IBM SPSS Statistics 20 version was used for the
analyses. Statistical signiﬁcance was set at the level of pr0.05.
3. Results
3.1. Sample
During the period of recruitment, 75 patients with FES were
consecutively admitted to the Psychiatric Clinic. Twenty-seven
patients were not included in the study: eight were lost at follow-
up; three refused to be revaluated; 16 were non-adherent to the
monthly visits or treatment and therefore they were excluded
from the study. The remaining 48 patients participated in the
study and were re-evaluated in 2010.
The SCID-IV re-administration conﬁrmed the diagnosis of
schizophrenia in all 48 patients. None of them was using
illicit drugs.
Eighteen patients (37.5%) satisﬁed the remission RSWG criteria
(R), while the remaining 30 patients (62.5%) did not (NR). Among
remitted patients, three of them (16.7%) were in complete symp-
tomatic recovery, nine (50%) showed minimal symptom severity
and six (33.3%) had mild symptom severity at follow-up.
The socio-demographics and clinical features at baseline were
reported in Table 1.
At the follow-up R and NR patients showed similar age
(R: 40.579.8 yrs; NR: 44.8711.7 yrs) (t¼1.3; p¼0.19) and
duration of illness (R: 16.074.8 yrs; NR: 16.375.1 yrs) (t¼0.1;
p¼0.85), while the number of psychotic episodes requiring
hospitalization were higher in NR (3.671.0) than in R (2.270.6)
(t¼4.7; po0.001).
3.2. Core symptoms severity
At baseline, the severity of core symptoms was lower in R than
in NR (Table 1). Furthermore, the severity criterion for remission
(item score r3) was already satisﬁed for unusual thought content,
blunted affect and social withdrawal more frequently in R than in
NR patients. Lastly, ﬁve out of the eight core symptoms already
satisﬁed the severity criterion for remission in most R patients
(n¼11; 61%) but only in a minority of NR patients (n¼3; 10%).
3.3. Core symptoms severity and prediction of remission
At baseline, among the core symptoms only the severity of
social withdrawal predicted the long-term outcome: this core
symptom was negatively associated with remission status at
follow-up (β¼2.1; wald¼11.7; OR¼0.11; CI 95%¼0.03–0.040;
p¼0.001). Moreover, gender, age at onset, DUP and working status
did not exert any effect on long-term symptomatic remission.
4. Discussion
In the present study patients with schizophrenia were evalu-
ated with the PANSS at their ﬁrst episode of illness and 16 years
thereafter.
At the time of their ﬁrst episode of illness, patients who
reached remission during the follow-up (R patients), showed a
lower severity of almost all core symptoms than NR; in fact, only
the severity of hallucinations and conceptual disorganization was
comparable in R and in NR. Interestingly, if applying the severity
criteria of the RSWG at the ﬁrst episode, most of the core
symptoms (unusual thought content, mannerisms, conceptual
disorganization, blunted affect and social withdrawal) would have
already satisﬁed such criteria in the majority (50–88%) of R
patients, whereas only mannerism would have satisﬁed this
criterion in most (53%) NR. In other words, in R patients the ﬁrst
episode was mainly characterized by delusions, hallucinations and
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behavioral disorganization; thus they might present a mild sever-
ity of the other core symptoms.
Indeed, the severity of the negative symptoms speciﬁcally
differentiated R and NR at the ﬁrst episode, since blunted affect,
social withdrawal and lack of spontaneity showed a lower severity
in R than in NR. Further, the core symptoms “blunted affect” and
“social withdrawal” satisﬁed the severity criteria for remission in
77–88% of R patients and in 36–23% in NR at illness onset. Finally,
among the core symptoms, only the severity of social withdrawal
at ﬁrst episode negatively predicted 16-year, long-term remission.
In a previous long-term study (Marchesi et al., 2014) negative
symptoms, already present in FES patients, remained stable
thorough the course of the illness, could not be considered as a
consequence of a chronic course, and exerted a negative effect on
the achievement of remission. This ﬁnding is in keeping with
recent studies indicating an association between higher negative
symptoms at ﬁrst episode and poor outcome (Kurihara et al., 2011;
Ayesa-Arriola et al., 2013; Lang et al., 2013).
This ﬁnding is in line with classical psychopathology, which
consider negative dimension as “fundamental” for the outcome of
schizophrenia (Kraepelin, 1899; Bleuler, 1911) probably implying
speciﬁc etio-pathogenetic pathways (Crow, 1985; Kirkpatrick
et al., 2001).
Interestingly, R and NR patients differed signiﬁcantly about
working status at the baseline, with a lower rate of NR patients
being employed. This ﬁnding conﬁrms that a worse premorbid
social functioning is associated with a non-remission (Lambert
et al., 2006; San et al., 2007; Wunderink et al., 2009; Karow et al.,
2012) and supports the suggestion that premorbid impairment in
social functioning may represent a precursor of negative symp-
toms (Strous et al., 2004; Allen et al., 2005; Chang et al., 2013).
Therefore, we can hypothesize that in our patients poor pre-
morbid social functioning can facilitate the onset of negative
symptoms, which in turn may reduce the likelihood to reach a
symptomatic remission.
Concerning positive core symptoms, R patients exhibited more
positive than negative symptoms at their ﬁrst episode. However,
logistic regression analysis demonstrated that the likelihood to
develop remission is not inﬂuenced by the severity of positive
symptoms, suggesting that positive symptoms at ﬁrst episode do
not have impact on later symptomatic remission. In a previous
long-term study (Marchesi et al., 2014) positive symptoms showed
a ﬂuctuating course and their prognostic value depended more on
their recurrence than of their initial severity.
Taken together, these ﬁndings suggest that: (1) patients who
achieved remission at follow-up presented a mild severity of the
core symptoms at their ﬁrst episode of illness; (2) speciﬁcally,
most R patients already showed, at illness onset, the severity of
the core symptoms requested for remission and (3) among the
core symptoms, social withdrawal seems to negatively inﬂuence
the achievement of remission.
Thus, the results of the present study suggest that at ﬁrst
episode lesser symptoms severity, particularly a lesser degree of
negative symptoms, predict long-term remission in schizophrenic
patients, conﬁrming the data of previous studies with a shorter
period of follow-up (Lasser et al., 2007; Novick et al., 2007;
Addington and Addington, 2008; Rossi et al., 2009; Ventura
et al., 2009; Lambert et al., 2010; Buoli et al., 2012; Ayesa-Arriola
et al., 2013; Lang et al., 2013). In addition, this study also suggests
that the operational criteria proposed by the RSWG might deﬁne a
subgroup of patients with milder core symptoms since their ﬁrst
episode of illness, and, hence, they could have a higher probability
to achieve long-term remission. Therefore, the RSWG remission
criteria (Andreasen et al., 2005) could tell more about severity of
the core symptoms at ﬁrst episode, than about remission itself.
This conclusion is particularly true for negative symptoms, since
the more severe is the social isolation at the ﬁrst episode, the less
probable the achievement of long-term remission.
The present study has the following limitations. First, the
symptoms severity was evaluated at onset and after a mean period
of 16 years of illness. However we can exclude that deep ﬂuctua-
tion of symptom severity may occur during the course of illness,
since symptoms severity was clinically monitored nearly at
monthly visits. Nonetheless, since schizophrenia is not a stable
disorder and remission, as well as recovery, is for many patients a
time limited occurrence, we cannot exclude that possible relapses
may occur. Second, even though the treatment was clinically
monitored at each visit and strategies to prevent non-adherence
were planned during the follow-up period, we cannot rule out that
some patients were non-adherent to medications between the
monthly visits.
In conclusion, according to the data of the present study, long-
term symptomatic remission, even though wished for all schizo-
phrenic patients, would seem a viable therapeutic outcome
Table 1
Socio-demographic and symptoms features at baseline in patients with ﬁrst
episode schizophrenia.
Remission at follow-up
Yes No
n. 18 n. 30
n. % n. % Fa p
Gender
Male 10 55.5 19 63.3 0.2 0.76
Marital status 3.6 0.19
Never married 13 72.2 22 73.3
Married 5 27.8 4 13.3
Divorced/Widowed 0 0.0 4 13.3
Working status 6.4 0.01
Never occupied 4 22.2 18 60.0
Occupied 14 77.8 12 40.0
Living status 0.5 0.54
Living alone 8 44.4 10 33.3
Living with someone 10 55.6 20 66.7
mean7S.D. mean7S.D. t p
Age at onset years 22.273.8 21.675.8 0.3 0.70
DUP weeks 18.074.5 19.774.4 1.2 0.20
PANSS scores
Positive score 24.873.7 28.174.0 2.7 0.008
Negative score 17.873.1 25.374.4 6.1 o0.001
General psychopathology score 46.074.1 55.875.4 6.6 o0.001
Total score 88.876.2 109.2710.0 7.7 o0.001
PANSS core items score
Delusions (P1) 4.770.7 5.370.8 2.4 0.02
Hallucinations (P3) 3.971.3 4.271.4 0.6 0.50
Unusual thought Content (G9) 3.570.7 4.470.9 3.2 0.002
Conceptual disorganization (P2) 3.571.3 3.870.9 0.9 0.32
Mannerisms/posturing (G5) 2.770.8 3.370.9 2.3 0.02
Blunted affect (N1) 3.070.6 3.670.8 2.8 0.007
Social withdrawal (N4) 2.770.6 4.170.8 5.5 o0.001
Lack of spontaneity (N6) 1.870.7 3.170.9 4.7 o0.001
PANSS scorer3 (yes) n. % n. % Fa p
Delusions (P1) 1 5.6 1 3.3 0.1 1.00
Hallucinations (P3) 6 33.3 8 26.7 0.2 0.74
Unusual thought content (G9) 9 50.0 5 16.7 6.0 0.02
Conceptual disorganization (P2) 9 50.0 8 26.7 2.6 0.12
Mannerisms/posturing (G5) 15 83.3 16 53.3 4.4 0.06
Blunted affect (N1) 14 77.8 11 36.7 7.6 0.008
Social withdrawal (N4) 16 88.9 7 23.3 19.3 o0.001
Lack of spontaneity (N6) 15 83.3 16 53.3 4.4 0.06
Z5 Items with a score r3 11 61.1 3 10.0 17.4 o0.001
a Fischer's exact test.
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particularly in patients with less severe core symptoms, particu-
larly negative symptoms, at their ﬁrst episode.
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